Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

  • Technology appraisal guidance
  • TA1109
  • Published: 

Suggested remit: To appraise the clinical and cost effectiveness of Darolutamide with androgen within its marketing authorisation for treating prostate cancer.

This page was last updated: